secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2026-08-04T20:02:18+00:00
Accession:  0001193125-26-332736
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q2 2026 revenue $72.8M; Revuforj net revenue $54.7M (+91% YoY); Niktimvo $60.3M (+67%)
--------------------------------------------------------------------------------

- Total revenue $72.8M (Revuforj $54.7M, Niktimvo collaboration $18.1M); H1 2026 net loss $49.4M vs $71.8M prior year.
- Cash $575.1M; expects profitability; full-year 2026 R&D+SG&A ~$400M excl. $50M stock comp.
- Pipeline expanded: SNDX-4321 (allosteric EGFR inhibitor for NSCLC) IND by end 2026; SNDX-62122 (menin inhibitor for MF) IND in 2027.
- Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD.
- Revuforj prescriptions ~1,500 in Q2 (+121% YoY); average treatment duration increasing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/0001193125-26-332736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-332736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer